Search results for "From Annals of Internal Medicine"
Medicare coverage of semaglutide would be costly
Covering semaglutide for patients who are overweight and have cardiovascular disease could cost Medicare an additional $34 to $145 billion annually, researchers estimated.
https://diabetes.acponline.org/archives/2024/09/13/7.htm
13 Sep 2024
Little difference in dementia risk with SGLT-2s vs. dulaglutide
Older patients with type 2 diabetes starting sodium-glucose cotransporter-2 (SGLT-2) inhibitors had an estimated difference of less than a percentage point in five-year risk of clinical onset of dementia compared with those starting the glucagon-like peptide-1 receptor agonist dulaglutide, a South Korean study found.
https://diabetes.acponline.org/archives/2024/09/13/6.htm
13 Sep 2024
Case report of DKA from a gout flare
A recently published case described a patient with a history of tophaceous gout who developed diabetic ketoacidosis (DKA) during a severe acute polyarticular gout flare.
https://diabetes.acponline.org/archives/2024/09/13/9.htm
13 Sep 2024
SGLT-2 inhibitors associated with improved outcomes in stage 5 CKD patients
Patients with type 2 diabetes and stage 5 chronic kidney disease (CKD) had lower risk of progressing to dialysis or having a cardiovascular event if they took sodium-glucose cotransporter-2 (SGLT-2) inhibitors, a study found.
https://diabetes.acponline.org/archives/2024/05/10/6.htm
10 May 2024
Latest Beyond the Guidelines, In the Clinic target diabetes
An endocrinologist and a nephrologist discuss appropriate care for type 2 diabetes and chronic kidney disease, and the evidence supporting type 2 diabetes prevention and treatment are reviewed.
https://diabetes.acponline.org/archives/2024/06/14/6.htm
14 Jun 2024
State caps on insulin costs for commercially insured didn't increase insulin use
Limits on out-of-pocket costs did lower patients' insulin expenses, but the effect was mostly limited to those with health savings accounts, a pre-post comparison among U.S. states found.
https://diabetes.acponline.org/archives/2024/04/12/6.htm
12 Apr 2024
Weekly insulin icodec superior to daily insulin analogues in latest manufacturer trial
Patients with type 2 diabetes who used weekly insulin icodec and a dosing app had greater reductions in HbA1c levels than similar patients randomized to start a daily insulin analogue with a traditional dosing strategy.
https://diabetes.acponline.org/archives/2023/10/13/6.htm
13 Oct 2023
Use of GLP-1 receptor agonists rose steeply in past decade, study finds
A million U.S. patients, mostly women, started taking glucagon-like peptide-1 (GLP-1) receptor agonists between 2011 and 2023, according to an analysis of medical records across the country.
https://diabetes.acponline.org/archives/2024/08/09/6.htm
9 Aug 2024
California's insulin plan, clinical decision support in lower-income countries
Recent articles from Annals of Internal Medicine discussed California's plan to produce insulin and a diabetes clinical decision support system that may be helpful in primary care in low- to middle-income countries.
https://diabetes.acponline.org/archives/2022/12/09/8.htm
9 Dec 2022
Insulin costs, diabetes and testosterone
An Ideas and Opinions piece explained some of the factors behind insulin prices, and a meta-analysis looked at testosterone levels in men with diabetes.
https://diabetes.acponline.org/archives/2023/09/08/6.htm
8 Sep 2023